image
Healthcare - Biotechnology - NASDAQ - US
$ 0.7812
2.52 %
$ 58.9 M
Market Cap
-1.08
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CUE stock under the worst case scenario is HIDDEN Compared to the current market price of 0.781 USD, Cue Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CUE stock under the base case scenario is HIDDEN Compared to the current market price of 0.781 USD, Cue Biopharma, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CUE stock under the best case scenario is HIDDEN Compared to the current market price of 0.781 USD, Cue Biopharma, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CUE

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
9.29 M REVENUE
69.16%
-41.5 M OPERATING INCOME
20.42%
-40.7 M NET INCOME
19.83%
-36.3 M OPERATING CASH FLOW
9.09%
32 K INVESTING CASH FLOW
-99.87%
10.2 M FINANCING CASH FLOW
-13.63%
1.58 M REVENUE
-52.76%
-9.63 M OPERATING INCOME
-9.28%
-9.5 M NET INCOME
-9.65%
-9.03 M OPERATING CASH FLOW
-19.94%
-1 K INVESTING CASH FLOW
-1.02%
-932 K FINANCING CASH FLOW
-9.49%
Balance Sheet Cue Biopharma, Inc.
image
Current Assets 25.1 M
Cash & Short-Term Investments 22.5 M
Receivables 945 K
Other Current Assets 1.73 M
Non-Current Assets 7.05 M
Long-Term Investments 0
PP&E 4.84 M
Other Non-Current Assets 2.21 M
69.77 %2.94 %5.39 %15.04 %6.87 %Total Assets$32.2m
Current Liabilities 13.7 M
Accounts Payable 2.82 M
Short-Term Debt 7.87 M
Other Current Liabilities 2.99 M
Non-Current Liabilities 1 M
Long-Term Debt 1 M
Other Non-Current Liabilities 0
19.21 %53.59 %20.37 %6.83 %Total Liabilities$14.7m
EFFICIENCY
Earnings Waterfall Cue Biopharma, Inc.
image
Revenue 9.29 M
Cost Of Revenue 0
Gross Profit 9.29 M
Operating Expenses 50.8 M
Operating Income -41.5 M
Other Expenses -826 K
Net Income -40.7 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)9m09m(51m)(41m)826k(41m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-446.86% OPERATING MARGIN
-446.86%
-437.97% NET MARGIN
-437.97%
-232.44% ROE
-232.44%
-126.35% ROA
-126.35%
-157.35% ROIC
-157.35%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cue Biopharma, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -40.7 M
Depreciation & Amortization 397 K
Capital Expenditures -66 K
Stock-Based Compensation 6.85 M
Change in Working Capital -4.92 M
Others -2.97 M
Free Cash Flow -36.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cue Biopharma, Inc.
image
Wall Street analysts predict an average 1-year price target for CUE of $4.17 , with forecasts ranging from a low of $2 to a high of $7 .
CUE Lowest Price Target Wall Street Target
2 USD 156.02%
CUE Average Price Target Wall Street Target
4.17 USD 433.37%
CUE Highest Price Target Wall Street Target
7 USD 796.06%
Price
Max Price Target
Min Price Target
Average Price Target
7766554433221100Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Cue Biopharma, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
30.9 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript) Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Business Officer Operator Good day, and welcome to the Cue Biopharma Business Update Call. All participants are in a listen-only mode. seekingalpha.com - 2 weeks ago
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases. globenewswire.com - 2 weeks ago
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.79, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.789. The aggregate gross proceeds of the offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.79 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about April 16, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma. globenewswire.com - 2 weeks ago
Cue Biopharma Announces Proposed Public Offering BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma. globenewswire.com - 2 weeks ago
Cue Biopharma to Host Business Update Call and Webcast BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. globenewswire.com - 2 weeks ago
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases. globenewswire.com - 2 weeks ago
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago. zacks.com - 1 month ago
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results. globenewswire.com - 1 month ago
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Company as inducement material to Dr. Baker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (“the Inducement Award”). globenewswire.com - 5 months ago
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024. globenewswire.com - 5 months ago
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Tops Revenue Estimates Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.24 per share a year ago. zacks.com - 5 months ago
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024. globenewswire.com - 5 months ago
8. Profile Summary

Cue Biopharma, Inc. CUE

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 58.9 M
Dividend Yield 0.00%
Description Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Contact 21 Erie Street, Cambridge, MA, 02139 https://www.cuebiopharma.com
IPO Date Jan. 2, 2018
Employees 41
Officers Dr. Ronald D. Seidel III, Ph.D. Co-Founder Dr. Rodolfo J. Chaparro Ph.D. Co-Founder & Senior Advisor Mr. Colin G. Sandercock J.D., MSE Senior Vice President, General Counsel & Secretary Dr. Matteo Levisetti M.D. Chief Medical Officer Ms. Lucinda Warren Chief Business Officer Ms. Kerri-Ann Millar CPA Chief Financial Officer Dr. Daniel G. Baker M.D., Ph.D. Interim Chief Development Officer Dr. Steven C. Almo Ph.D. Co-Founder and Chairman of Scientific & Clinical Advisory Board Mr. Daniel R. Passeri J.D., M.Sc. Chief Executive Officer & Director